We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

7 hedge funds and large institutions have $228K invested in Phio Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

182% more capital inflows, than outflows

Capital inflows: $98.8K | Capital outflows: $35K

1.51% more ownership

Funds ownership: 3.69% → 5.2% (+1.5%)

0% more funds holding

Funds holding: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$55.1K
2
Virtu Financial
Virtu Financial
New York
+$18.4K
3
SG Americas Securities
SG Americas Securities
New York
+$16.1K
4
HSBC Holdings
HSBC Holdings
United Kingdom
+$5.74K
5
UBS Group
UBS Group
Switzerland
+$3.45K

Top Sellers

Rank Fund Capital Flow
1
CVI Holdings
CVI Holdings
Delaware
-$26K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$9K

PHIO Hedge Fund Activity: Q4 2019 in Review

7 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2019, worth a combined $228K — down 12% from $259K a quarter earlier.

Fund positioning in PHIO was balanced in Q4 2019: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $55.1K. The largest seller was CVI Holdings, exiting entirely with an estimated $26K sold.

  • 7 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $228K of Phio Pharmaceuticals stock for Q4 2019, down 12% quarter-over-quarter.
  • 2 funds opened new Phio Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of 0 holders.
  • The largest Phio Pharmaceuticals buyer in Q4 2019 was Renaissance Technologies, an estimated $55.1K added.
  • The largest Phio Pharmaceuticals seller in Q4 2019 was CVI Holdings, an estimated $26K sold.

Based on aggregated 13F filings for Q4 2019.